{"prompt": "['CONFIDENTIAL', 'Given that many potential subjects have cardiovascular disease and hypertension, there is', 'potential for symptomatic reduction in blood pressure with restful sitting in the study chair', 'during the procedures in those subjects taking antihypertensive medications. In some cases', 'this may be associated with feelings of nausea. Maintaining hydration and repositioning in', 'the chair should resolve these problems.', 'All efforts will be made to minimize these risks by using only trained personnel who are', 'experienced and skilled in using the devices. Moreover, all TMS sessions will be performed in', 'a medical setting with access to a skilled medical team and life-support equipment.', 'Page 16 of 57']['CONFIDENTIAL', '3.0 study objectiveS', '3.1. PRIMARY OBJECTIVES', 'To determine whether NBS guided 1Hz rTMS targeting the motor representation areas of', 'hand muscles on the healthy brain hemisphere has a beneficial effect on the motor recovery', 'of the corresponding stroke-affected muscles when combined with standardized task-', 'oriented motor rehabilitation.', 'Primary outcome measure: Upper-extremity Fugl-Meyer score.', 'The beneficial effect of 1Hz NBS guided rTMS will be established if a statistically', 'signicantly greater proportion of patients receiving NBS-rTMS attain clinically important', 'improvement in the primary outcome measure than patients receiving sham-rTMS', 'between baseline and 6 months post-treatment.', '3.2', 'SECONDARY OBJECTIVES', 'Secondary outcome measures for the study are:', 'Absolute change in points on UEFM', 'Action-Research Arm Test (ARAT)', 'NIH Stroke Scale (NIHSS)', 'The changes on these scales between baseline and 6 months post-treatment will be determined', 'for both therapy groups and the groups compared to each other to establish effects of therapy.', 'Quality of life outcomes:', \"In addition to the other secondary outcome measures above the patients' quality of life will be\", 'assessed using the EQ-5D questionnaire. The change on this scale between baseline and 6', 'months post-treatment will be determined for both therapy groups and the groups compared to', 'each other to establish effects of therapy on quality of life.', 'Assessment of safety:', 'To assess safety of study device use, all Serious Adverse Events, Unanticipated Adverse', 'Device Events and Device Related Adverse Events will be recorded and compared between', 'therapy groups.', 'Page 17 of 57']['CONFIDENTIAL', '4.0 study design', 'This is a prospective multi-center sham-controlled double-blinded study.', '4.1. SELECTION OF SUBJECTS', 'This trial will include volunteers who meet eligibility criteria and agree to participate in the', 'study. The purpose of the study including risks and benefits will be explained to potential', 'participants who will then be asked to sign an informed consent form. Potential participants', 'will be screened for inclusion and exclusion criteria.', '60 patients will be randomized to the study (for rationale see section 6.1 Power analysis).', 'Additional subjects may be recruited to compensate patients lost from follow-up or withdrawn', 'from the study.', '4.2.', 'SUBJECT SELECTION CRITERIA', 'Candidates for this study must meet ALL of the following inclusion criteria and NONE of the', 'exclusion criteria:', 'Inclusion Criteria :', '> 18 years of age', 'An ischemic stroke suffered 3-12 months prior to the study;', 'no other known brain abnormalities by history;', 'A one-sided stroke resulting in upper extremity paresis', 'A Chedoke-McMaster Stroke Assessment arm stage and hand stage of 3-6 for the', 'affected limb', 'Exclusion Criteria', 'Implanted metallic parts of implanted electronic devices, including pacemakers,', 'defibrillators, or implant medication pump;', 'Pregnant or trying to become pregnant; Lack of pregnancy established in females of', 'child-bearing potential by a negative urine pregnancy test at screening.', 'Active alcohol abuse, illicit drug use or drug abuse or significant mental illness', 'Patients suffering from depression as measured by a score of >10 on the Patient Health', 'Questionnaire (PHQ9). For clarity, patients diagnosed with depression which is', 'controlled with stable anti-depressive medication and in whom PHQ9 is <10 are', 'eligible to participate in the trial.', 'History of epilepsy, defined as at least two unprovoked seizures occurring greater than', '24 hours apart or diagnosis of an epilepsy syndrome, and no seizures within the last 12', 'months.', 'Any condition that would prevent the subject from giving voluntary informed consent;', 'An implanted brain stimulator;', 'Any metal in head with the exception of dental work or any ferromagnetic metal elsewhere', 'in the body ;', 'Enrolled or plans to enroll in an interventional trial during this study;', 'Scalp wounds or infections;', 'Page 18 of 57']\n\n###\n\n", "completion": "END"}